GLP-1 receptor agonists (such as semaglutide or dulaglutide) are linked to a higher risk of gallbladder and biliary complications, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis).
Key Risks and Findings
* Increased Risk: Studies and pharmacovigilance data show a heightened risk of gallstones and biliary events, especially with longer treatment duration, higher doses, and use for weight loss.
* Specific Agents: Real-world data point to higher cholelithiasis rates with agents like semaglutide and dulaglutide.
* Rapid Weight Loss Factor: Rapid or significant weight loss—regardless of how it is achieved—causes the liver to secrete excess cholesterol into the bile, which contributes to stone formation.
Why GLP-1 Agonists Affect the Gallbladder
* Slower Gallbladder Emptying: GLP-1 medications suppress cholecystokinin (CCK) and alter gut signals, which reduces gallbladder contraction and causes bile stasis (sludge and slow-moving bile).
* Bile Acid Signaling: Alterations in bile acid receptors (such as FXR and TGR5) further impair normal biliary flow and lipid handling.
Warning Signs to Watch For
Seek urgent medical care if you experience symptoms of a gallbladder attack or infection:
* Severe, persistent pain in the upper-right or central abdomen
* Nausea and recurring vomiting
* Jaundice (yellowing of the skin or the whites of the eyes)
* Fever or chills accompanying abdominal pain
Note: Routine gallbladder imaging is generally not required before starting GLP-1 therapy unless you have a history of gallstones or biliary disease.
相關報導轉自 Source: https://share.google/uXbUmXzbr4UcfHqcH